Actively Recruiting
Implementation of a Protocol for the Transdifferentiation of Buccal Mucosal Epithelium Into Corneal Epithelium
Led by University Hospital, Montpellier · Updated on 2024-08-19
4
Participants Needed
1
Research Sites
49 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Montpellier
Lead Sponsor
I
Institute for Neuroscience Montpellier
Collaborating Sponsor
AI-Summary
What this Trial Is About
Objectives The transparent surface of the eye, called the cornea, plays a crucial role in transmitting light to the retina and in protecting the eye. On its external surface, the cornea is composed of a constantly renewing multistratified epithelium. This mechanism is fueled by stem cells located in the limbus (the transition zone between the cornea and the sclera). Limbal Stem Cell Deficiency (LSCD) is characterized by a decrease or cessation of epithelial renewal and neovascularization of the cornea. Consequently, the cornea loses its integrity and transparency. This visually impairing condition is currently in a therapeutic impasse as only autologous limbal or allogeneic corneal grafts are viable options, but they pose significant risks to patients. Studies have shown that the oral cavity contains stem cells that can be isolated, cultured, and transdifferentiated into limbal stem cells (LSCs). However, to date, these studies are limited, and no protocol has been validated. In this study, the advantage of the accessibility of the oral cavity is used to develop a protocol for differentiating cells from the oral mucosa into limbal stem cells (LSCs) for use in a future clinical trial with patients. Methodology This prospective monocentric study will be conducted on patients from the ophthalmology department of the Montpellier University Hospital who have an indication for conjunctival reconstruction. After obtaining consent from the patients, cells from the oral wall will be sent to the tissue bank of the Montpellier University Hospital, where they will be cultured. Finally, the transdifferentiation steps will be analyzed by the "Eye" research team at the Institute of Neuroscience in Montpellier, which is collaborating on the project. The investigators have established objective factors to assess the success of the developed protocol based on the literature : (i) \> 3% of stem cells in primary cultures, (ii) \<10% aborted colonies, (iii) Expression of LSC markers (Pax6, Krt14, p63).
CONDITIONS
Official Title
Implementation of a Protocol for the Transdifferentiation of Buccal Mucosal Epithelium Into Corneal Epithelium
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Indication for conjunctival reconstruction using oral mucosa, such as recurrent pterygium, conjunctival carcinoma, or ocular burn
- Written consent to participate in the research
You will not qualify if you...
- Presence of chronic infections such as HIV, hepatitis, tuberculosis, or Lyme disease
- Oral diseases affecting the health of oral mucosa as determined by the doctor
- Uncontrolled systemic illnesses
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Gui de Chauliac - Service d'Ophtamologie
Montpellier, Occitanie, France, 34295
Actively Recruiting
Research Team
V
Vincent Daien, MD PhD
CONTACT
H
Hannah Crowdy
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here